Abstract:Background The interplay between the gut microbiome and immune responses in cancer remains poorly understood. We showed that gut microbiome changes are closely associated with development of lung adenocarcinoma (LUAD) in a human-relevant, tobacco-associated mouse model (Gprc5a-/-; G).1 Knockout of the antimicrobial protein Lcn2 (Gprc5a-/-/Lcn2-/-; GL) further reduced microbial diversity while enhancing inflammation and tumor development.1 We thus hypothesized that microbial dysbiosis in the gut, such as that incurred by loss of Lcn2, may exacerbate LUAD development and influence response to immune checkpoint blockade (ICB). Methods We used fecal microbiota transfer (FMT) in syngeneic and tobacco carcinogenesis models. Gut microbiome composition was assessed using 16S rDNA-Seq analysis, chemokines were quantified in murine sera, and the tumor immune microenvironment (TIME) and gut immune milieu were comprehensively studied using single-cell RNA-sequencing and flow cytometry. Results Syngeneic G mice receiving FMT from GL donors (G < GL) exhibited significantly increased tumor growth compared to G < G mice. This effect was recapitulated in an independent syngeneic model (KrasG12D LKR13 cells in wild-type mice) and tobacco carcinogen-exposed G < GL mice. Analysis of fecal pellets using 16S rDNA-Seq revealed significant differences in gut beta diversity between G < G and G < GL mice, with elevated abundance of tumor-promoting Alistipes2 and reduced levels of immunotherapy-favorable taxa Ruminoccocus and Akkermansia.3 Flow cytometry analysis of the colonic lamina propria demonstrated an inflamed environment in G < GL mice with increased inflammatory immune cell frequency. This local gut inflammation was accompanied by a systemic inflammatory response, as indicated by elevated inflammatory chemokines in the sera. Single-cell RNA-sequencing and flow cytometry analysis of tumors revealed an enhanced immunosuppressive phenotype in the TIME of G < GL mice, including increased fractions of T regulatory and exhausted T cells, along with reduced levels of activated T cells. Flow cytometry confirmed enhanced immunosuppression in G < GL mice, including increased fractions of myeloid-derived suppressor cells in the TIME. The dysbiotic gut, with its associated systemic inflammation and immunosuppression of the TIME, significantly impacted the response to ICB, with G < GL mice demonstrating reduced response and sensitivity to anti-PD1 treatment compared to G < G mice. Conclusions Our findings show that gut microbiome dysbiosis fosters lung cancer development by promoting immunosuppression, perhaps via a local and systemic gut microbiota-immune system crosstalk (figure 1). Modulating the gut microbiome may offer promising strategy for interception or early treatment of lung cancer. Acknowledgements Supported in part by National Cancer Institute (NCI) grants R01CA205608 and R01CA248731 (to H. Kadara). References Finnicum CT, Rahal Z, Hassane M, Treekitkarnmongkol W, Sinjab A, Morris R, Liu Y, Tang EL, Viet S, Petersen JL, et al. Pathogenesis of Tobacco-Associated Lung Adenocarcinoma Is Closely Coupled with Changes in the Gut and Lung Microbiomes. Int J Mol Sci. 2022;23(18):10930. Available online: https://doi.org/10.3390/ijms231810930 Moschen AR, Gerner RR, Wang J, Klepsch V, Adolph TE, Reider SJ, Hackl H, Pfister A, Schilling J, Moser PL, Kempster SL, Swidsinski A, Orth Höller D, Weiss G, Baines JF, Kaser A, Tilg H. Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations. Cell Host Microbe. 2016;19(4):455–469. doi: 10.1016/j.chom.2016.03.007 Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27(3):504–514. doi: 10.1038/s41591–020-01224–2

Pathogenesis of Tobacco-Associated Lung Adenocarcinoma Is Closely Coupled with Changes in the Gut and Lung Microbiomes

1330 Gut Microbiome Dysbiosis Promotes Immune Suppression and Lung Cancer Development

From tobacco smoking to mutational signature: the role of epigenetic changes in human cancers

Inflammation mediated by gut microbiome alterations promotes lung cancer development and an immunosuppressed tumor microenvironment

Unveiling microbial dynamics in lung adenocarcinoma and adjacent nontumor tissues: insights from nicotine exposure and diverse clinical stages via nanopore sequencing technology

Abstract 2883: Gut Microbiome Dysbiosis Promotes Immune Suppression and Lung Cancer Development

Genome-Wide Gene Expression Changes in the Normal-Appearing Airway During the Evolution of Smoking-Associated Lung Adenocarcinoma.

From Tobacco Smoking to Cancer Mutational Signature: a Mediation Analysis Strategy to Explore the Role of Epigenetic Changes

Smoker and non-smoker lung adenocarcinoma is characterized by distinct tumor immune microenvironments.

Interaction between the microbiome and TP53 in human lung cancer

Exposure to a Mixture of Cigarette Smoke Carcinogens Disturbs Gut Microbiota and Influences Metabolic Homeostasis in A/J Mice.

Activation of 5-Lipoxygenase is Required for Nicotine Mediated Epithelial-Mesenchymal Transition and Tumor Cell Growth

Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival

The Function and Molecular Mechanism of Commensal Microbiome in Promoting Malignant Progression of Lung Cancer

Abstract 6513: Single cell and spatial profiling reveal molecular and immune evolution from precancers to invasive lung adenocarcinomas in genetic and carcinogen-induced mouse models

Convergent alteration of lung tissue microbiota and tumor cells in lung cancer

Figure S1 from Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment

Identification and validation of smoking-related genes in lung adenocarcinoma using an in vitro carcinogenesis model and bioinformatics analysis

Tobacco smoke alters the landscape of mutation, selection, and epistasis in lung adenocarcinoma

Association Studies on Gut and Lung Microbiomes in Patients with Lung Adenocarcinoma

LKB1 Phosphorylation and Deactivation in Lung Cancer by NNAL, a Metabolite of Tobacco-Specific Carcinogen, in an Isomer-Dependent Manner